Software as a Medical Device (SaMD) Regulatory Guide

Introduction

The term Software as a Medical Device (SaMD) was coined by the International Medical Device Regulators Forum (IMDRF). To manage it correctly, you must first distinguish it from SiMD (Software in a Medical Device).

• SiMD: Software that drives a physical device (e.g., firmware for a pacemaker). It is regulated as part of the hardware.
• SaMD: Stand-alone software that provides clinical information to diagnose, treat, or prevent a condition (e.g., an AI-based app that detects skin cancer from smartphone photos).

Understanding this boundary is the first step in SaMD risk management, as stand-alone software requires a completely different approach to clinical evidence and quality control.

The IMDRF SaMD Framework: Classification Levels

Unlike traditional devices categorized by “Class I, II, or III,” SaMD regulatory classification follows a specific matrix based on two factors:

1. The state of the healthcare situation: Is the condition Critical, Serious, or Non-serious?
2. The importance of the information provided: Does the software Treat/Diagnose, Drive Clinical Management, or merely Inform Clinical Management?

This results in four IMDRF levels (I-IV):

• Level I: Lowest risk (e.g., software to inform clinical management for a non-serious condition).
• Level IV: Highest risk (e.g., software used to diagnose a critical condition like a stroke in real-time)

Clinical Evaluation of SaMD: Proving the Algorithm

One of the most rigorous parts of the journey is the clinical evaluation of SaMD. You cannot measure “mechanical wear” on an algorithm; instead, you must prove its clinical validity through three pillars:

• Valid Clinical Association: Does the software’s output actually relate to the clinical condition?
• Analytical Validation: Does the software correctly process the input data (technical accuracy)?
• Clinical Validation: Does the software yield a clinically meaningful result in the target population?

For high-risk SaMD, clinical validation of software often requires prospective clinical trials to prove that the “digital therapy” or “digital diagnosis” is safe and effective.

Quality Management System (QMS) for SaMD

While ISO 13485 remains the gold standard, a Quality Management System (QMS) for SaMD must be adapted for iterative development. Traditional “manufacturing” controls are replaced by:

• Release Management: Ensuring that the version being downloaded by users is exactly the version that was validated.
• Cybersecurity Controls: Since SaMD often lives on mobile devices or in the cloud, security is a core QMS pillar.
• Design Controls for Iteration: Managing how a software “patch” or “update” is documented without restarting the entire regulatory submission.

SaMD Risk Management: Beyond Hardware Failure

SaMD risk management under ISO 14971 requires a shift in mindset. Risks in software are usually systematic, not random. Key areas of focus include:

• Data Integrity: What happens if the input data is corrupted?
• User Interpretation: What if the doctor misinterprets a software-generated chart?
• Algorithmic Bias: Is the software less accurate for certain patient demographics?

SaMD Lifecycle Management: The “Continuous” Challenge

The SaMD lifecycle management process is never truly “finished.” Because software allows for continuous improvement, manufacturers must decide when a change is a “minor bug fix” and when it is a “significant change” that requires a new regulatory filing.

The industry is moving toward “Total Product Lifecycle” (TPLC) approaches, where regulators look at the manufacturer’s ability to monitor real-world performance and update the software safely.

Visure’s Role: Orchestrating SaMD Compliance

Managing SaMD without a specialized tool is a recipe for regulatory rejection. Visure Requirements ALM provides the structure needed for stand-alone software:

• IMDRF Classification Support: Automatically apply the correct documentation rigor based on your SaMD level.
• Clinical Evidence Traceability: Link clinical requirements directly to validation test results to build a robust Clinical Evaluation Report (CER).
• Agile-Ready Compliance: Support rapid Sprints while the system automatically maintains the traceability link required by auditors.
• Vivia AI Integration: Use AI to check if your software requirements are “testable” and “unambiguous,” which is critical for the analytical validation phase.

Conclusion

Software as a Medical Device (SaMD) represents the future of personalized medicine. However, the path to market requires a deep understanding of the IMDRF SaMD framework and a commitment to rigorous clinical validation. By moving away from “hardware thinking” and embracing a lifecycle-based approach to quality and risk, manufacturers can deliver digital solutions that are not only innovative but fundamentally safe for patients.

In the world of SaMD, your code is your “clinical intervention.” Treat it with the same respect and rigor you would a surgical instrument.

Check out the free trial at Visure and experience how AI-driven change control can help you manage changes faster, safer, and with full audit readiness.